drugset / Trial / NCT05777369
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of R-CMOP regimen based on mitoxantrone hydrochloride liposome injection in the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL) based on cardiac function screening
Timeline
- Start
- 2023-03
- Primary completion
- 2023-08
- Completion
- 2024-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 18 mg/m2 | — |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | — |
| Subject | Vindesine | Small molecule | 3 mg/m2 | — |